On 14th February 2014 GlaxoSmithKline announced they are to start the Phase III trial of Mepolizumab.

This trial will be to evaluate the efficacy and safety of Mepolizumab antibody to treat patients with Eosinophilic Granulomatosis with Polyangiitis - EGPA (formerly known as Churg Strauss Syndrome - CSS).


The Centres involved in the trial are:

Portsmouth Hospital (Prof Anoop Chauhan),

Addenbrooke’s University of Cambridge (Dr David Jayne),

University of Oxford (Prof Rasshid Luqmani), and

University Hospital Leicester (Prof Andrew Wardlow).